SOHO 2021 | B-ALL patient selection for treatment with blinatumomab
Rachel Rau, MD, of Baylor College of Medicine, Houston, TX, explains the rationale behind patient selection for treatment with the bispecific T-cell engager (BiTE) blinatumomab for B-cell acute lymphoblastic leukemia (B-ALL). Dr Rau discusses data from trials, including the AA1331 trial (NCT02101853), where blinatumomab has demonstrated efficacy as a bridge to transplant. Dr Rau also talks on the use of blinatumomab for patients who remain measurable residual disease (MRD)-positive after chemotherapy but are in complete remission, and patients who experience high levels of toxicity with chemotherapy. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Rachel Rau, MD, has participated in consultancy work with Jazz and Servier.
